FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096784971> ?p ?o ?g. }

• W3096784971 endingPage "390" @default.
• W3096784971 startingPage "381" @default.
• W3096784971 abstract "Background Isocitrate dehydrogenase ( IDH1 and IDH2 ) mutations commonly co‐occur with FMS‐like tyrosine kinase 3 ( FLT3 ) mutations in patients with acute myeloid leukemia (AML). Methods The authors reviewed cases of patients with FLT3 ‐internal tandem duplication ( FLT3 ‐ITD)–mutated AML with concurrent IDH mutations diagnosed between January 2011 and December 2018. Results A total of 91 patients with FLT3 ‐ITD and IDH1 or IDH2 “double‐mutated” AML were identified; 36 patients had concurrent FLT3 ‐ITD/ IDH1 mutations (18 in the frontline and 18 in the recurrent and/or refractory [R/R] setting) and 55 patients had concurrent FLT3 ‐ITD/ IDH2 mutations (37 in the frontline and 18 in the R/R setting). FLT3 and/or IDH inhibitors ( FLT3 Is and/or IDH Is) were given as a single agent or in combination with cytotoxic chemotherapy (CCT) or low‐intensity therapy (LIT). Rates of complete remission (CR) plus CR with incomplete count recovery (CRi) with the use of CCT and FLT3 Is were 100% and 64%, respectively, in patients in the frontline and R/R settings. CCT with IDH Is was given in 2 frontline patients and both achieved a CR. LIT with FLT3 Is in the frontline and R/R settings demonstrated CR and CRi rates of 67% and 28%, respectively. Single‐agent FLT3 Is and IDH Is demonstrated limited activity with a CR and/or CRi rate of 14% in patients with disease in the R/R setting. Conclusions The combination of FLT3 I‐based therapy with CCT or LIT appeared to be effective in both the frontline and R/R settings among patients with FLT3 ‐ITD/ IDH co‐mutated disease. Fewer patients with double‐mutated disease received CCT or LIT with IDH1/2 inhibitor in the frontline setting; however, high response rates also were noted with this approach. Lay Summary The prognostic influence of FMS‐like tyrosine kinase 3–internal tandem duplication ( FLT3 ‐ITD) and isocitrate dehydrogenase ( IDH ) co‐mutation status on outcomes in patients with acute myeloid leukemia receiving an FLT3 inhibitor, non– FLT3 / IDH inhibitor–based regimens, or an IDH inhibitor is unclear. This is an important clinical question because multiple targeted therapies for FLT3 and IDH1/2 mutations have become available. The results of the current study demonstrated that a combination of a FLT3 inhibitor with cytotoxic chemotherapy or low‐intensity therapy appears to be an effective approach in patients with FLT3 ‐ITD/ IDH co‐mutated disease in both the frontline and recurrent and/or refractory settings. Fewer dual‐mutated patients received cytotoxic chemotherapy or low‐intensity therapy with an IDH1/2 inhibitor in the frontline setting; however, excellent responses also were observed with this approach." @default.
• W3096784971 created "2020-11-09" @default.
• W3096784971 creator A5000750846 @default.
• W3096784971 creator A5010663972 @default.
• W3096784971 creator A5015140142 @default.
• W3096784971 creator A5020340537 @default.
• W3096784971 creator A5022647201 @default.
• W3096784971 creator A5022932599 @default.
• W3096784971 creator A5029750735 @default.
• W3096784971 creator A5030500582 @default.
• W3096784971 creator A5035605515 @default.
• W3096784971 creator A5035622739 @default.
• W3096784971 creator A5040192170 @default.
• W3096784971 creator A5049385583 @default.
• W3096784971 creator A5050041791 @default.
• W3096784971 creator A5051949215 @default.
• W3096784971 creator A5055045706 @default.
• W3096784971 creator A5056317446 @default.
• W3096784971 creator A5059373442 @default.
• W3096784971 creator A5059747862 @default.
• W3096784971 creator A5061026876 @default.
• W3096784971 creator A5069176297 @default.
• W3096784971 creator A5080350639 @default.
• W3096784971 creator A5088307376 @default.
• W3096784971 creator A5090435894 @default.
• W3096784971 creator A5091492845 @default.
• W3096784971 date "2020-10-29" @default.
• W3096784971 modified "2023-10-15" @default.
• W3096784971 title "Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent <i>FLT3</i>‐ITD and <i>IDH</i> mutations" @default.
• W3096784971 cites W1847894796 @default.
• W3096784971 cites W2053968609 @default.
• W3096784971 cites W2063092678 @default.
• W3096784971 cites W2073101822 @default.
• W3096784971 cites W2078481381 @default.
• W3096784971 cites W2092589411 @default.
• W3096784971 cites W2128586106 @default.
• W3096784971 cites W2137103862 @default.
• W3096784971 cites W2159507916 @default.
• W3096784971 cites W2317475893 @default.
• W3096784971 cites W2592164001 @default.
• W3096784971 cites W2624245118 @default.
• W3096784971 cites W2715749014 @default.
• W3096784971 cites W2750794123 @default.
• W3096784971 cites W2806682325 @default.
• W3096784971 cites W2890413816 @default.
• W3096784971 cites W2902301444 @default.
• W3096784971 cites W2909346948 @default.
• W3096784971 cites W2912675416 @default.
• W3096784971 cites W2980399650 @default.
• W3096784971 cites W3021794778 @default.
• W3096784971 cites W4376595466 @default.
• W3096784971 doi "https://doi.org/10.1002/cncr.33293" @default.
• W3096784971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33119202" @default.
• W3096784971 hasPublicationYear "2020" @default.
• W3096784971 type Work @default.
• W3096784971 sameAs 3096784971 @default.
• W3096784971 citedByCount "9" @default.
• W3096784971 countsByYear W30967849712021 @default.
• W3096784971 countsByYear W30967849712022 @default.
• W3096784971 countsByYear W30967849712023 @default.
• W3096784971 crossrefType "journal-article" @default.
• W3096784971 hasAuthorship W3096784971A5000750846 @default.
• W3096784971 hasAuthorship W3096784971A5010663972 @default.
• W3096784971 hasAuthorship W3096784971A5015140142 @default.
• W3096784971 hasAuthorship W3096784971A5020340537 @default.
• W3096784971 hasAuthorship W3096784971A5022647201 @default.
• W3096784971 hasAuthorship W3096784971A5022932599 @default.
• W3096784971 hasAuthorship W3096784971A5029750735 @default.
• W3096784971 hasAuthorship W3096784971A5030500582 @default.
• W3096784971 hasAuthorship W3096784971A5035605515 @default.
• W3096784971 hasAuthorship W3096784971A5035622739 @default.
• W3096784971 hasAuthorship W3096784971A5040192170 @default.
• W3096784971 hasAuthorship W3096784971A5049385583 @default.
• W3096784971 hasAuthorship W3096784971A5050041791 @default.
• W3096784971 hasAuthorship W3096784971A5051949215 @default.
• W3096784971 hasAuthorship W3096784971A5055045706 @default.
• W3096784971 hasAuthorship W3096784971A5056317446 @default.
• W3096784971 hasAuthorship W3096784971A5059373442 @default.
• W3096784971 hasAuthorship W3096784971A5059747862 @default.
• W3096784971 hasAuthorship W3096784971A5061026876 @default.
• W3096784971 hasAuthorship W3096784971A5069176297 @default.
• W3096784971 hasAuthorship W3096784971A5080350639 @default.
• W3096784971 hasAuthorship W3096784971A5088307376 @default.
• W3096784971 hasAuthorship W3096784971A5090435894 @default.
• W3096784971 hasAuthorship W3096784971A5091492845 @default.
• W3096784971 hasBestOaLocation W30967849711 @default.
• W3096784971 hasConcept C104317684 @default.
• W3096784971 hasConcept C121332964 @default.
• W3096784971 hasConcept C126322002 @default.
• W3096784971 hasConcept C127848430 @default.
• W3096784971 hasConcept C142424586 @default.
• W3096784971 hasConcept C143998085 @default.
• W3096784971 hasConcept C181199279 @default.
• W3096784971 hasConcept C185592680 @default.
• W3096784971 hasConcept C2776059313 @default.
• W3096784971 hasConcept C2776694085 @default.
• W3096784971 hasConcept C2777150147 @default.
• W3096784971 hasConcept C2778729363 @default.

• next